superfamily and is situated on the apical membrane of the enterocyte. Its expression in the human adult jejunum is at least more than 2 to 10 times higher than that of other transporters such as from the ABC-transporter family (MDR1, MRP2, or BCRP) or from the solute carrier (SLC) family (OATP's) (Hilgendorf et al., 2007) . In histologically normal intestinal biopsies from 10 adults, PEPT1 was expressed most abundantly in duodenum and ileum with a mean relative mRNA expression of 4 compared to <0.5 in colon (Meier et al., 2007) . In 6 adult intestine organ donors the PEPT1 protein expression accounted for approximately 50% of the total expression of all transporter proteins in the small intestine. In colon, PEPT1 represents 5% of all transporter proteins (Drozdzik et al., 2014) .
PEPT1 is best known for its function as a nutrient-derived di-and tripeptide transporter, but may also have a role in (pro)drug transport because it is the most abundant peptide transporter in the gut and drug properties mimicking di-and tripeptides may allow uptake by the peptide transporter (Brandsch, 2013) . Its role as intestinal transporter has been demonstrated for several (pro)drugs. In PepT1 (orthologue of human PEPT1) knock-out mice, the small intestinal uptake of the pro-drug valacyclovir was attributed for 90% to the PepT1 transporter . Consequently these mice had a delayed T max and decreased C max of acyclovir (active metabolite of valacyclovir) relative to wild type mice .In human adults, however, PEPT1 mRNA expression was not correlated with valacyclovir pharmacokinetic parameters, even though, in vitro, valacyclovir was a PEPT1 substrate (Landowski et al., 2003) . This suggests that valacyclovir may be not be a PEPT1 substrate in human adults, or that PEPT1 mRNA expression may not correlate to PEPT1 activity. The role of PEPT1 in valacyclovir pharmacokinetics in humans may differ from that in animals and remains to be elucidated. Several 6 with varying affinities: e.g. ceftibuten, cyclacillin, cefadroxil, cefaclor, benzylpenicillin, and cephalexin. Their structure resembles the tripeptide structure with additional groups (Brandsch et al., 2008) . The ACE-inhibitor fosinopril is a PEPT1 substrate; other ACE-inhibitors might be substrates, although this needs to be confirmed (Brandsch et al., 2008) .
Most drugs prescribed to children are administered orally. Some PEPT1 substrates are dosed to children even very early in life. Considering the wide age-related variation in the processes affecting oral drug absorption, including gastric pH, gastric motility and drug metabolizing enzyme activity, age-related changes in membrane transporters are also very likely (Mooij et al., 2012) . Earlier we showed a transporter-dependent maturation in gene expression in young infants for MDR1, MRP2 and OATP2B1 (Mooij et al., 2014) , but overall data on the intestinal expression of membrane transporters during growth and development are very scarce (Brouwer et al., 2015) .
To the best of our knowledge, studies on the development of intestinal PEPT1 in humans are lacking. From a pharmacological point a view, it is important to elucidate the development of PEPT1 expression for known substrates. But this may also be for the development of new drugs in which PEPT1 could enhance oral absorption.
PEPT1 developmental changes have been studied in several animal species. A developmental pattern of PepT1 mRNA and protein expression has been shown in the duodenum, jejunum, ileum and colon of rats (Shen et al., 2001 ). In the small intestine of newborn rats the expression peaked 3-5 days after birth, after which it rapidly decreased and increased again by the time animals were weaning. The authors ascribed the increase postpartum to suckling. In another study in rats, PepT1 small intestinal mRNA expression was stable from postnatal day 4 till day 21, and then decreased from postnatal day 50 onwards (Rome et al., 2002) . In neonatal miniature pigs, PepT1 mediated dipeptide
7 disappearance in the ileal segment was highest in the youngest age group (1 week) , but PepT1 expression in post-weaned pigs was higher than in sucklings (Nosworthy et al., 2013) . These data suggest that in the first weeks of life, intestinal PEPT1 is important for nutritional intake and later for diet transition following weaning
Comparative mRNA expression of various peptide transporters in mice, rats and human adults shows a PEPT1 expression in all species, but expression levels varied in relation to that of other peptide transporters (HPT1, PEPT2) (Kim et al., 2007) . This suggests that animal data cannot be directly extrapolated to humans and that human studies are needed.
To our knowledge expression or activity of PEPT1 in human fetal or pediatric population has not been described thus far, let alone a developmental expression pattern. (Puiman et al., 2011) . The Erasmus MC research ethics board in two other protocols approved collection of intestinal residual tissue from adolescent patients and endoscopy biopsies of older children and adolescents.
Informed consent was obtained from all parents/care-givers and children older than 12 years of age for use of left-over tissue and clinical data.
Real-Time Reverse-Transcription Polymerase Chain Reaction (real time RT-PCR)
Isolation and cDNA synthesis has been previously described (Mooij et al., 2014) . In brief, frozen tissue samples were mechanically homogenized on ice. RNA was extracted using the RNeasy Mini Kit (Qiagen). To digest genomic DNA remnants, RNA was treated with DNase. The RNA integrity numbers (RIN) of the samples were analyzed using the 2100 BioAnalyzer (Agilent, Santa Clara, CA), and a value <5 was considered poor quality and reason to discard the 1 0 and OATP2B1 staining, microwave pretreatment in citrate buffer (10 mM, pH6.0) was used to retrieve antigens. In case of MRP2, pepsin pretreatment, similar as for PEPT1, was used.
Primary antibodies mouse anti-MDR1 and mouse anti-MRP2 were obtained from EMD Millipore, and rabbit anti-OATP2B1 from Abnova. PEPT1 staining intensity was microscopically scored by two independent observers (low-1, moderate-2 or high-3).
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RESULTS

Descriptive results
Twenty-six samples (n=20 neonates/infants, n=2 children, n=4 adolescents) were collected ( and adults, rat and mice (Groneberg et al., 2001; Hussain et al., 2002; Ziegler et al., 2002; Laforenza et al., 2010) .
Based on the clear developmental expression patterns of intestinal drug metabolizing enzymes and hepatic transporters, with in general low expression at birth and increasing with postnatal age, we anticipated lower PEPT1 transporter expression in neonates (Brouwer et al., 2015) . However, our results suggest slightly lower PEPT1 expression and similar localization as in adolescents. Hence the uptake of PEPT1 substrates in neonates and young infants is likely not to be affected by growth and maturation and dose-adjustments for PEPT1 activity therefore do not seem necessary. Nevertheless, adjustment of drug dosing of PEPT1 substrates may be needed in young children for other reasons, e.g. if the drug is metabolized or renally cleared, which may result in age-related changes in disposition.
Stable mRNA expression of small intestinal MDR1 from neonatal age onwards was also found in other studies (Fakhoury et al., 2005; Miki et al., 2005; Mizuno et al., 2013; Mooij et al., 2014) . In a previous study from our group, MRP2 mRNA expression in the small intestines was also stable during infant age, but OATP2B1 expression in neonates was about three times D M D 6 8 8 0 9
1 5 higher than in adults (Mooij et al., 2014) . This suggests that intestinal membrane transporters show stable or higher expression during childhood and that a developmental expression might occur before birth. These findings are supported by our immunohistochemistry data, which show clear localization of PEPT1 and the other transporters studied. Immunohistochemical staining of MDR1, MRP2 and OATP2B1 was done to compare the localization of PEPT1 in relation to the other transporters. MDR1 was stained at the apical border of the enterocyte, similar to MDR1 staining in 59 duodenal biopsies from infants up to 7 years of age and from fetuses from a gestational age of 16 and 20 weeks (van Kalken et al., 1992; Fakhoury et al., 2005) . MRP2
apical staining matches to staining in human colorectal cancer tissue, as well as intestinal tissue from horse, rabbits and rats (Mottino et al., 2000; Van Aubel et al., 2000; Tyden et al., 2010) .
Intraepithelial OATP2B1 staining at the basolateral enterocyte border was similar to staining in human colonic biopsies from adults (Kleberg et al., 2012) . The localization corresponds with the function of MDR1, MRP2 and PEPT1 to facilitate uptake of substrates in the enterocyte, whereas OATP2B1 facilitates excretion from the enterocyte to blood (Klaassen and Aleksunes, 2010) .
Our data do not contradict previous data from juvenile animal studies. In rats, PepT1 expression was increased on days 3 to 5 after birth, after which it rapidly decreased and then increased at the time animals were weaning (Shen et al., 2001 ). If we would extrapolate this data to neonates, we would expect a PEPT1 elevation several days after birth, and time of weaning might be translated to infant age at the time of introducing food next to breastfeeding of formula. The slightly higher PEPT1 expression in older children and adolescents than in young infants might be compared to weaned rats from the animal study. Still, a clinical impact of slightly lower infantile PEPT1 expression is questionable.
PEPT1 has been studied in relation to feeding and nutrition (Spanier, 2014) .
Interestingly, the PEPT1 transporter expression seems sensitive to nutritional status. In adult D M D 6 8 8 0 9
1 6 short-bowel syndrome patients, small intestinal and colonic mRNA expression of PEPT1 was upregulated compared to healthy controls (Ziegler et al., 2002) . Studies in several animal species have further explored the impact of nutrition on intestinal PEPT1 expression. After maternal overnutrition during pregnancy (but not after maternal undernutrition), PepT1 mRNA expression was significantly increased in jejunum of newborn or weaned piglets (Cao et al., 2014) . In contrast, maternal protein restriction in rats also led to higher duodenal PepT1 mRNA expression in 3-and 16-week-old offspring. Irrespective of feeding, PepT1 mRNA expression in 16-week-old rats was higher than in 3-week-old rats (Pinheiro et al., 2013) . In another study in adult rats on a protein-rich diet, PepT1 mRNA and protein expressions, as well as transporter activity were increased (Shiraga et al., 1999) . In low-birth-weight piglets colonic PepT1 activity (measured by flux of cephalexin) was increased after high-instead of normal-protein formula feeding (Boudry et al., 2014) . The effects of feeding and nutrition may in part explain the observed interindividual variability in PEPT1 gene expression in young infants in the present study. Unfortunately the available nutritional data were too diverse and partially lacking to test this hypothesis. Moreover, immunohistochemistry is not the preferred method to quantify the observed changes. Other approaches such as Western Blots are more informative, but tissue was lacking to perform this analysis..
Several hormones (insulin, leptin, growth hormone) appear to induce PEPT1 activity in Caco-2 cells (Thamotharan et al., 1999; Buyse et al., 2001; Alteheld et al., 2005) . Also, dexamethasone was shown to enhance PepT1 activity in Xenopus oocytes and mice, but human data are, to our knowledge, lacking (Rexhepaj et al., 2009 ). In our cohort, a large proportion of premature neonates have very likely been exposed prenatally to betamethasone as a routine for the prevention of respiratory distress syndrome in imminent premature birth.
Unfortunately, informed consent was lacking to retrieve prenatal corticosteroid use by the mother from the medical charts. Hence, our data should be interpreted with caution, taking into D M D 6 8 8 0 9
1 7 account a potential effect of prenatal corticosteroid exposure on the observed intestinal PEPT1 expression.
Several limitations of this study should be addressed. One, most samples were obtained during the first few weeks of life, and pediatric samples after the age of 4 months up to 9 years are lacking. Therefore the expression in this age range is still unknown. Second, variability in our samples might be due to co-medication, nutritional differences, disease or extent of inflammation. Still, most samples were obtained during surgery of stoma closure and therefore the intestinal tissue can be expected to be relatively normal. Third, variability might be due by genetic polymorphisms in SLC15A1 gene causing a change in PEPT1 expression. Thus far, no polymorphism has been proven to be clinically relevant, however, and therefore we did not genotype our samples (Anderle et al., 2006 ).
In conclusion, although small intestinal PEPT1 expression was slightly lower in neonates than in older children, this difference is small and tissue distribution is similar. Therefore, this finding suggests similar oral absorption of PEPT1 substrates across the pediatric age range. 
